CY1124279T1 - Ανοσοθεραπεια βασισμενη στη 2,3 διοξυγοναση της ινδολεαμινης - Google Patents
Ανοσοθεραπεια βασισμενη στη 2,3 διοξυγοναση της ινδολεαμινηςInfo
- Publication number
- CY1124279T1 CY1124279T1 CY20211100572T CY211100572T CY1124279T1 CY 1124279 T1 CY1124279 T1 CY 1124279T1 CY 20211100572 T CY20211100572 T CY 20211100572T CY 211100572 T CY211100572 T CY 211100572T CY 1124279 T1 CY1124279 T1 CY 1124279T1
- Authority
- CY
- Cyprus
- Prior art keywords
- ido
- cancer
- treatment
- relates
- indoleamine
- Prior art date
Links
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 title 1
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 abstract 6
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 abstract 6
- 238000011282 treatment Methods 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 102000007079 Peptide Fragments Human genes 0.000 abstract 2
- 108010033276 Peptide Fragments Proteins 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 230000005975 antitumor immune response Effects 0.000 abstract 1
- 229940022399 cancer vaccine Drugs 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
- C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
- C12Y113/11052—Indoleamine 2,3-dioxygenase (1.13.11.52), i.e. indoleamine 2,3-dioxygenase 1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με το πεδίο της προφύλαξης και της θεραπείας του καρκίνου. Ειδικότερα, παρέχεται η πρωτεΐνη 2,3-διοξυγονάση της ινδολεαμίνης (IDO) ή πεπτιδικά θραύσματα αυτής που είναι ικανά να προκαλέσουν αντικαρκινικές ανοσολογικές αποκρίσεις. Συγκεκριμένα, η εφεύρεση σχετίζεται με τη χρήση της IDO ή πεπτιδίων που προέρχονται από αυτήν ή ειδικών για την IDO κυττάρων Τ για τη θεραπεία του καρκίνου. Συνεπώς, η εφεύρεση σχετίζεται με ένα αντικαρκινικό εμβόλιο το οποίο μπορεί προαιρετικά να χρησιμοποιηθεί σε συνδυασμό με άλλες ανοσοθεραπείες και με ειδικά για την IDO κύτταρα Τ που μεταφέρονται επαγωγικά ή επάγονται in vivo με εμβολιασμό ως θεραπεία για τον καρκίνο. Μια πτυχή της εφεύρεσης είναι ότι τα φάρμακα που παρέχονται στο παρόν μπορούν να χρησιμοποιηθούν σε συνδυασμό με χημειοθεραπεία κατά του καρκίνου. Μια περαιτέρω πτυχή σχετίζεται με την πρόληψη και τη θεραπεία λοιμώξεων με τους ίδιους τρόπους όπως περιγράφεται παραπάνω. Παρέχεται επίσης η χρήση της IDO και των ανοσογόνων πεπτιδικών θραυσμάτων αυτής στη θεραπεία, τη διάγνωση και την πρόγνωση του καρκίνου και των λοιμώξεων.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200800565 | 2008-04-17 | ||
EP09753556.1A EP2280721B1 (en) | 2008-04-17 | 2009-04-17 | Indoleamine 2, 3-dioxygenase based immunotherapy |
PCT/DK2009/000095 WO2009143843A1 (en) | 2008-04-17 | 2009-04-17 | Indoleamine 2, 3-dioxygenase based immunotherapy |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1124279T1 true CY1124279T1 (el) | 2022-07-22 |
Family
ID=40873320
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20181100171T CY1120352T1 (el) | 2008-04-17 | 2018-02-12 | Ανοσοθεραπεια βασισμενη στη 2,3 διοξυγοναση της ινδολεαμινης |
CY20211100572T CY1124279T1 (el) | 2008-04-17 | 2021-06-28 | Ανοσοθεραπεια βασισμενη στη 2,3 διοξυγοναση της ινδολεαμινης |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20181100171T CY1120352T1 (el) | 2008-04-17 | 2018-02-12 | Ανοσοθεραπεια βασισμενη στη 2,3 διοξυγοναση της ινδολεαμινης |
Country Status (20)
Country | Link |
---|---|
US (6) | US9433666B2 (el) |
EP (3) | EP3915570A1 (el) |
JP (2) | JP2011520783A (el) |
CN (2) | CN102088994B (el) |
AU (1) | AU2009253539B2 (el) |
CA (1) | CA2721150C (el) |
CY (2) | CY1120352T1 (el) |
DK (2) | DK3320912T3 (el) |
ES (2) | ES2870596T3 (el) |
HR (2) | HRP20180282T1 (el) |
HU (2) | HUE055338T2 (el) |
IL (1) | IL208781A (el) |
LT (2) | LT3320912T (el) |
NO (1) | NO2280721T3 (el) |
NZ (1) | NZ588757A (el) |
PL (2) | PL2280721T3 (el) |
PT (2) | PT2280721T (el) |
SI (2) | SI3320912T1 (el) |
WO (1) | WO2009143843A1 (el) |
ZA (1) | ZA201008056B (el) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011520783A (ja) | 2008-04-17 | 2011-07-21 | エルレフ ホスピタル | インドールアミン2,3−ジオキシゲナーゼに基づく免疫療法 |
EP2425830A1 (en) * | 2010-09-03 | 2012-03-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Synergistic drug combination for the treatment of cancer |
GB201315946D0 (en) * | 2013-09-06 | 2013-10-23 | Immune Targeting Systems Its Ltd | Oncology vaccine |
EP3149047A1 (en) * | 2014-05-29 | 2017-04-05 | Spring Bioscience Corporation | Anti- indoleamine 2,3-dioxygenase 1 antibodies and diagnostic uses thereof |
CA2959197C (en) * | 2014-09-17 | 2023-03-14 | Herlev Hospital | Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof |
CN106148276A (zh) * | 2015-04-16 | 2016-11-23 | 中国科学院上海生命科学研究院 | 间充质干细胞在制备治疗神经退行性疾病的药物中的应用 |
BR112017027653A2 (pt) | 2015-06-29 | 2018-08-28 | Ose Immunotherapeutics | método para induzir a resposta de memória t precoce com vacina anti-tumoral de peptídeos curtos |
US11298413B2 (en) | 2015-09-16 | 2022-04-12 | Io Biotech Aps | Vaccine compositions comprising C—C motif chemokine 22 (CCL22) or fragments thereof |
PL3423087T3 (pl) * | 2016-03-04 | 2024-05-20 | Io Biotech Aps | Skojarzona terapia przeciwnowotworowa |
CN109803674A (zh) | 2016-06-10 | 2019-05-24 | Io生物技术公司 | Calr和jak2疫苗组合物 |
JP2019537432A (ja) * | 2016-10-04 | 2019-12-26 | ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド | 標的化エフェクタータンパク質およびその使用 |
DK3526347T3 (da) * | 2016-10-14 | 2021-02-15 | Univ Zuerich | Indolamin-2,3-dioxygenase-analyse til diagnose og prognose af prostatacancer |
EA201991444A1 (ru) | 2017-01-27 | 2019-12-30 | Имматикс Байотекнолоджиз Гмбх | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака |
HRP20230512T8 (hr) | 2017-01-27 | 2023-09-15 | Immatics Biotechnologies Gmbh | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma jajnika i drugih karcinoma |
MA47367B1 (fr) * | 2017-01-27 | 2023-06-28 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers |
WO2019075062A1 (en) | 2017-10-11 | 2019-04-18 | University Of Florida Research Foundation | MODIFIED GAL-1 PROTEINS AND USES THEREOF |
KR102624844B1 (ko) | 2017-11-27 | 2024-01-12 | 오제 이뮈노테라프틱스 | 암의 향상된 치료 |
CN109758467B (zh) * | 2019-03-08 | 2020-12-25 | 中国农业科学院兰州兽医研究所 | 一种吉西他滨在制备预防口蹄疫病毒感染的药物中的应用 |
KR20220092905A (ko) * | 2019-10-23 | 2022-07-04 | 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 | 입양 면역요법 |
CN112881269A (zh) * | 2021-02-23 | 2021-06-01 | 浙江正熙生物技术股份有限公司 | 一种流式荧光检测试剂的质量检测方法 |
GB202103673D0 (en) | 2021-03-17 | 2021-04-28 | Io Biotech Aps | Combination therapy for cancer |
WO2023161350A1 (en) | 2022-02-24 | 2023-08-31 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
CN114657158B (zh) * | 2022-05-25 | 2022-10-21 | 深圳吉诺因生物科技有限公司 | Ido1相关疫苗及其应用 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US58767A (en) | 1866-10-16 | John brougjbton | ||
US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
BR9608804A (pt) * | 1995-06-20 | 1999-02-17 | Merck & Co Inc | Processos para sintetizar (1s,2r) indandiol para sintetizar (1s) amino (2r) indanol substancialmente isento de qualquer estereoisômero de bio-resolução para remover cis (1s,2r) indandiol de uma mistura de cis (1s,2r) indandiol e cis (1r,2s) indandiol e cultura pura |
US6096313A (en) | 1996-02-09 | 2000-08-01 | Ludwig Institute For Cancer Research | Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant |
EP0956046A4 (en) | 1996-06-12 | 2004-10-20 | Yajun Guo | CELLULAR VACCINALS AND IMMUNOTHERAPEUTICS AND METHOD FOR THE PRODUCTION THEREOF |
CN1223688A (zh) * | 1996-06-27 | 1999-07-21 | 纳幕尔杜邦公司 | 对羟基苯丙酮酸双加氧酶的植物基因 |
DE19730066A1 (de) * | 1997-07-14 | 1999-01-21 | Basf Ag | DNA-Sequenz codierend für eine Hydroxyphenylpyruvatdioxygenase und deren Überproduktion in Pflanzen |
US6451840B1 (en) | 1997-12-05 | 2002-09-17 | Medical College Of Georgia Research Institute, Inc. | Regulation of T cell-mediated immunity by tryptophan |
WO2000066764A1 (en) | 1999-05-03 | 2000-11-09 | Ludwig Institute For Cancer Research | Methods for increasing t cell proliferation |
MXPA03006617A (es) | 2001-01-24 | 2004-12-02 | Protein Design Labs Inc | Metodos de diagnostico de cancer de pecho, composiciones y metodos de rastreo de moduladores de cancer de pecho. |
AU2002258518A1 (en) | 2001-03-14 | 2002-09-24 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer |
AU2002318944A1 (en) | 2001-08-01 | 2003-02-17 | Coley Pharmaceutical Gmbh | Methods and compositions relating to plasmacytoid dendritic cells |
WO2003020884A2 (en) | 2001-08-14 | 2003-03-13 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services | Method for rapid generation of mature dendritic cells |
EP2177601A1 (en) | 2002-04-12 | 2010-04-21 | Medical College of Georgia Research Institute, Inc | Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance |
US7763251B2 (en) | 2002-04-12 | 2010-07-27 | Medical College Of Georgia Research Institute, Inc. | Kits to assess the risk of tumor progression |
DE10229872A1 (de) * | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
US20040253606A1 (en) | 2002-11-26 | 2004-12-16 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
AU2003302820A1 (en) | 2002-12-05 | 2004-06-30 | Diadexus, Inc. | Compositions, splice variants and methods relating to breast specific genes and proteins |
EP1569690B1 (en) | 2002-12-13 | 2011-07-27 | Mitra Medical Technology AB | Antilymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent |
DE10261223A1 (de) | 2002-12-20 | 2004-07-08 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen |
EP1613308A4 (en) | 2003-03-27 | 2008-02-20 | Lankenau Inst Medical Res | CANCER TREATMENT METHODS |
US7598287B2 (en) | 2003-04-01 | 2009-10-06 | Medical College Of Georgia Research Institute, Inc. | Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities |
US20050186289A1 (en) | 2003-04-01 | 2005-08-25 | Medical College Of Georgia Research Institute, Inc. | Regulation of T cell-mediated immunity by D isomers of inhibitors of indoleamine-2,3-dioxygenase |
WO2005017163A2 (en) | 2003-08-15 | 2005-02-24 | Imperial College Innovations Limited | Phenotypic knockout of cell-surface proteins |
WO2005036127A2 (en) | 2003-10-02 | 2005-04-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for identifying target cell cytolytic lymphocytes in a sample |
EP1773846A4 (en) * | 2004-07-13 | 2008-10-08 | Univ British Columbia | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) |
US20060110371A1 (en) | 2004-11-23 | 2006-05-25 | Institut Pasteur | Control of indoleamine 2,3 deoxygenase expression and activity |
ES2523172T3 (es) | 2005-02-04 | 2014-11-21 | Survac Aps | Vacuna de péptido de survivina |
SG10201809390QA (en) | 2005-05-10 | 2018-11-29 | Incyte Holdings Corp | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
US7468186B2 (en) | 2005-07-22 | 2008-12-23 | City Of Hope | Polyomavirus cellular epitopes and uses therefor |
GB0519303D0 (en) | 2005-09-21 | 2005-11-02 | Oxford Biomedica Ltd | Chemo-immunotherapy method |
CA2953782C (en) * | 2005-09-23 | 2023-09-12 | Centro Superior De Investigaciones Cientificas | Cell populations having immunoregulatory activity, method for isolation and uses |
WO2007095050A2 (en) | 2006-02-09 | 2007-08-23 | Incyte Corporation | N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase |
WO2007115068A2 (en) | 2006-03-30 | 2007-10-11 | Indiana University Research And Technology Corporation | Genetic variants in the indoleamine 2,3-dioxygenase gene |
EP2023715B1 (en) * | 2006-05-18 | 2014-01-08 | Lankenau Institute for Medical Research | Indoleamine-2, 3-dioxygenase-2 |
WO2008085828A2 (en) * | 2007-01-03 | 2008-07-17 | The Johns Hopkins University | Peptide modulators of angiogenesis and use thereof |
JP2011520783A (ja) | 2008-04-17 | 2011-07-21 | エルレフ ホスピタル | インドールアミン2,3−ジオキシゲナーゼに基づく免疫療法 |
-
2009
- 2009-04-17 JP JP2011504314A patent/JP2011520783A/ja active Pending
- 2009-04-17 LT LTEP17194619.7T patent/LT3320912T/lt unknown
- 2009-04-17 CN CN200980122844.0A patent/CN102088994B/zh active Active
- 2009-04-17 ES ES17194619T patent/ES2870596T3/es active Active
- 2009-04-17 PL PL09753556T patent/PL2280721T3/pl unknown
- 2009-04-17 AU AU2009253539A patent/AU2009253539B2/en active Active
- 2009-04-17 LT LTEP09753556.1T patent/LT2280721T/lt unknown
- 2009-04-17 HU HUE17194619A patent/HUE055338T2/hu unknown
- 2009-04-17 SI SI200932129T patent/SI3320912T1/sl unknown
- 2009-04-17 PT PT97535561T patent/PT2280721T/pt unknown
- 2009-04-17 EP EP21157371.2A patent/EP3915570A1/en active Pending
- 2009-04-17 DK DK17194619.7T patent/DK3320912T3/da active
- 2009-04-17 CA CA2721150A patent/CA2721150C/en active Active
- 2009-04-17 NO NO09753556A patent/NO2280721T3/no unknown
- 2009-04-17 HU HUE09753556A patent/HUE037973T2/hu unknown
- 2009-04-17 PL PL17194619T patent/PL3320912T3/pl unknown
- 2009-04-17 US US12/988,124 patent/US9433666B2/en active Active
- 2009-04-17 DK DK09753556.1T patent/DK2280721T3/da active
- 2009-04-17 PT PT171946197T patent/PT3320912T/pt unknown
- 2009-04-17 EP EP09753556.1A patent/EP2280721B1/en active Active
- 2009-04-17 SI SI200931791T patent/SI2280721T1/en unknown
- 2009-04-17 WO PCT/DK2009/000095 patent/WO2009143843A1/en active Application Filing
- 2009-04-17 EP EP17194619.7A patent/EP3320912B1/en active Active
- 2009-04-17 NZ NZ588757A patent/NZ588757A/en unknown
- 2009-04-17 ES ES09753556.1T patent/ES2657963T3/es active Active
- 2009-04-17 CN CN201410247727.XA patent/CN104056261B/zh active Active
-
2010
- 2010-10-17 IL IL208781A patent/IL208781A/en active IP Right Grant
- 2010-11-10 ZA ZA2010/08056A patent/ZA201008056B/en unknown
-
2015
- 2015-03-17 JP JP2015052888A patent/JP6016966B2/ja active Active
-
2016
- 2016-08-08 US US15/231,075 patent/US10258678B2/en active Active
-
2018
- 2018-02-12 CY CY20181100171T patent/CY1120352T1/el unknown
- 2018-02-15 HR HRP20180282TT patent/HRP20180282T1/hr unknown
-
2019
- 2019-01-29 US US16/261,114 patent/US11324813B2/en active Active
-
2021
- 2021-05-13 HR HRP20210766TT patent/HRP20210766T1/hr unknown
- 2021-06-28 CY CY20211100572T patent/CY1124279T1/el unknown
-
2022
- 2022-03-17 US US17/697,732 patent/US20220202922A1/en not_active Abandoned
- 2022-04-15 US US17/721,577 patent/US11648302B2/en active Active
-
2023
- 2023-04-10 US US18/298,263 patent/US20230233657A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124279T1 (el) | Ανοσοθεραπεια βασισμενη στη 2,3 διοξυγοναση της ινδολεαμινης | |
CY1123762T1 (el) | Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενου του γαστρεντερικου και του γαστρiκου καρκινου | |
CY1121691T1 (el) | Εξατομικευμενη ανοσοθεραπεια εναντι ογκων των νευρωνων και του εγκεφαλου | |
CY1119219T1 (el) | Anti-ceacam5 αντισωματα και χρησεις αυτων | |
CL2017001819A1 (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón, incluido el cáncer de pulmón amicrocítico y otros tipos de cáncer | |
CY1123563T1 (el) | Ανοσογονικα wt-1 πεπτιδια και μεθοδοι χρησης αυτων | |
CY1122453T1 (el) | Νεα ανοσοθεραπεια εναντι διαφορων ογκων, οπως καρκινος του πνευμονα, οπου συμπεριλαμβανεται nsclc | |
CY1121789T1 (el) | Νεες ανοσοενισχυτικες συνθεσεις | |
CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
CY1124738T1 (el) | Συνθεσεiς εμβολιων που περιλαμβανουν τρυπτοφανη 2,3-διοξυγεναση ή θραυσματα αυτης | |
EA201791150A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака | |
CY1122483T1 (el) | Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης | |
BR122019014468B8 (pt) | uso de peptídeos de mhc de classe ii derivados de survivina | |
CY1123743T1 (el) | Αντισωμα igf-ir και χρηση του ως ουσια-οχημα διευθυνσιοδοτησης για την αγωγη του καρκινου | |
CY1116653T1 (el) | Msi-ειδικα πεπτιδια μετατοπισης πλαισιου (fsp) για προληψη και θεραπεια καρκινου | |
CY1122110T1 (el) | Εξατομικευμενα εμβολια για τον καρκινο | |
CY1124813T1 (el) | Καινοτομα πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια εναντι του ηπατοκυτταρικου καρκινωματος (hcc) και αλλων μορφων καρκινου | |
CY1125328T1 (el) | Ανασυνδυασμενο εμβολιο ιου λευχαιμιας αιλουροειδων περιεχοντας βελτιστοποιημενο γονιδιο φακελου ιου λευχαιμιας αιλουροειδων | |
CY1122083T1 (el) | Καινοτομος ανοσοθεραπεια εναντι ορισμενων ογκων του αιματος, οπως της οξειας μυελογεους λευχαιμιας (ομλ) | |
CY1118707T1 (el) | Her2 dna εμβολιο ως συμπληρωματικη αγωγη για καρκινους σε ζωα συντροφιας | |
MX2019012083A (es) | Nueva vacuna de peptidos contra la pcsk9. | |
EA201990670A1 (ru) | ВАКЦИНЫ НА ОСНОВЕ мРНК В ЛИПИДНЫХ НАНОЧАСТИЦАХ | |
CY1116819T1 (el) | Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενου του γαστρεντερικου και γαστρικου καρκινου |